Zymeworks Inc (ZYME)

$24.04 +0.42 (1.78%)
Market Cap 1.69B
Revenue (ttm) 105.97M
Net Income (ttm) -81.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 23.69
Profit Margin -76.56%
Debt to Equity Ratio 0.00
Volume 550,000
Avg Vol 806,132
Day's Range N/A - N/A
Shares Out 73.75M
Stochastic %K 29%
Beta 1.23
Analysts Strong Sell
Price Target $40.08

Company Profile

Zymeworks Inc., a biotechnology company, manages a portfolio of licensed healthcare assets and develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
mostbullish
mostbullish Mar. 18 at 12:44 PM
$ZYME very nice pCE 30% @ 6w 🤩 that is a fast acting agent !!! Clearly the double binding is proving its biological thesis. Support further succes in BC as was hinted via the string GEA data.
0 · Reply
StockNews_Live
StockNews_Live Mar. 18 at 11:49 AM
$ZYME 🎯 STOCK NEWS ALERT 💵 Price: $24.10 (+1.78%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zymeworks Inc. announced that its partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera (zanidatamab-hrii) at the American Association for… 📎 https://stocknews.live/news/ZYME/zymeworks-announces-presentations-for-ziihera-zanidatamab-hrii-at-xk6khj9mw286.html
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 10:47 AM
$ZYME RSI: 49.56, MACD: 0.1280 Vol: 0.83, MA20: 23.86, MA50: 23.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockNews_Live
StockNews_Live Mar. 17 at 9:08 PM
$ZYME 🎯 STOCK NEWS ALERT 💵 Price: $24.10 (+1.78%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zymeworks Inc. announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research… 📎 https://stocknews.live/news/ZYME/zymeworks-to-present-clinical-and-preclinical-data-on-adc-programs-xbwvsdnernm8.html
0 · Reply
BuyingSheep
BuyingSheep Mar. 13 at 4:27 PM
$ZYME what a dump the last days. 🤡🤡🤡
1 · Reply
Nickhzap
Nickhzap Mar. 12 at 7:41 PM
$ZYME oh now. I’m only up 160% now 😭😭😭😭😭😭😭
0 · Reply
BuyingSheep
BuyingSheep Mar. 12 at 2:41 PM
$ZYME all profits from previous days just evaporated. 😂🤡🤡🤡🤡
1 · Reply
BuyingSheep
BuyingSheep Mar. 10 at 2:53 PM
$ZYME the bigger the pump, the harder the dump
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Mar. 10 at 2:49 PM
$ZYME lmfao sheep farmer screenshoting a 100 share order at $16 Monday morning I can't stop laughing
0 · Reply
JFDI
JFDI Mar. 10 at 2:25 PM
Damn $ZYME
0 · Reply
Latest News on ZYME
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 18, 2026, 7:46 AM EDT - 1 hour ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 16 hours ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Mar 4, 2026, 10:45 AM EST - 13 days ago

Zymeworks FY25 Review: From Milestone Volatility To 2026 Upside

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Mar 2, 2026, 9:17 PM EST - 15 days ago

Zymeworks Inc. (ZYME) Q4 2025 Earnings Call Transcript

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:01 AM EST - 16 days ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 6:00 AM EST - 16 days ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Feb 12, 2026, 6:00 AM EST - 4 weeks ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Announces Participation in Upcoming Investor Conferences

Jan 27, 2026, 6:00 AM EST - 7 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:15 PM EST - 2 months ago

Zymeworks Inc. (ZYME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Jan 12, 2026, 6:00 AM EST - 2 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Jan 12, 2026, 3:59 AM EST - 2 months ago

HERIZON-GEA-01 Trial Highlights Zymeworks' Path To $440M Milestones And Growth

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jan 11, 2026, 6:00 PM EST - 2 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Jan 6, 2026, 1:34 PM EST - 2 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 11:23 PM EST - 3 months ago

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 3 months ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA

Nov 21, 2025, 9:11 AM EST - 4 months ago

Zymeworks: Adjusting My Levels After Ziihera's Phase III Data For GEA

Zymeworks: A Lot Of Moving Parts

Nov 19, 2025, 2:10 PM EST - 4 months ago

Zymeworks: A Lot Of Moving Parts

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Nov 18, 2025, 5:08 PM EST - 4 months ago

Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 4 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 4 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

Nov 17, 2025, 2:43 PM EST - 4 months ago

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

JAZZ

Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Nov 17, 2025, 1:45 PM EST - 4 months ago

Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Nov 17, 2025, 12:09 PM EST - 4 months ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

JAZZ

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 4 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 4 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 12:06 AM EST - 4 months ago

Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 4 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 5 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 5 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 5 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 5 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 5 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Sep 2, 2025, 6:09 PM EDT - 7 months ago

Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Sep 2, 2025, 12:30 PM EDT - 7 months ago

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 7 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 4:33 PM EDT - 7 months ago

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 8 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 8 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Jun 12, 2025, 4:34 PM EDT - 9 months ago

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 10 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 10 months ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 10 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:00 PM EDT - 11 months ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 11 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Apr 28, 2025, 5:33 PM EDT - 11 months ago

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Zymeworks: Poised For Growth With Platform Validation

Apr 28, 2025, 10:48 AM EDT - 11 months ago

Zymeworks: Poised For Growth With Platform Validation

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 11 months ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

mostbullish
mostbullish Mar. 18 at 12:44 PM
$ZYME very nice pCE 30% @ 6w 🤩 that is a fast acting agent !!! Clearly the double binding is proving its biological thesis. Support further succes in BC as was hinted via the string GEA data.
0 · Reply
StockNews_Live
StockNews_Live Mar. 18 at 11:49 AM
$ZYME 🎯 STOCK NEWS ALERT 💵 Price: $24.10 (+1.78%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zymeworks Inc. announced that its partner, Jazz Pharmaceuticals, will present four abstracts featuring data from clinical trials evaluating Ziihera (zanidatamab-hrii) at the American Association for… 📎 https://stocknews.live/news/ZYME/zymeworks-announces-presentations-for-ziihera-zanidatamab-hrii-at-xk6khj9mw286.html
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 10:47 AM
$ZYME RSI: 49.56, MACD: 0.1280 Vol: 0.83, MA20: 23.86, MA50: 23.52 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockNews_Live
StockNews_Live Mar. 17 at 9:08 PM
$ZYME 🎯 STOCK NEWS ALERT 💵 Price: $24.10 (+1.78%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Zymeworks Inc. announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research… 📎 https://stocknews.live/news/ZYME/zymeworks-to-present-clinical-and-preclinical-data-on-adc-programs-xbwvsdnernm8.html
0 · Reply
BuyingSheep
BuyingSheep Mar. 13 at 4:27 PM
$ZYME what a dump the last days. 🤡🤡🤡
1 · Reply
Nickhzap
Nickhzap Mar. 12 at 7:41 PM
$ZYME oh now. I’m only up 160% now 😭😭😭😭😭😭😭
0 · Reply
BuyingSheep
BuyingSheep Mar. 12 at 2:41 PM
$ZYME all profits from previous days just evaporated. 😂🤡🤡🤡🤡
1 · Reply
BuyingSheep
BuyingSheep Mar. 10 at 2:53 PM
$ZYME the bigger the pump, the harder the dump
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Mar. 10 at 2:49 PM
$ZYME lmfao sheep farmer screenshoting a 100 share order at $16 Monday morning I can't stop laughing
0 · Reply
JFDI
JFDI Mar. 10 at 2:25 PM
Damn $ZYME
0 · Reply
Nickhzap
Nickhzap Mar. 10 at 2:17 PM
$ZYME
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 10 at 2:04 PM
$ZYME What can I say . Me and zyme are finely tuned 😉
0 · Reply
NyseDayTrader
NyseDayTrader Mar. 10 at 2:03 PM
$ZYME
0 · Reply
erevnon
erevnon Mar. 9 at 6:57 PM
Evercore ISI Group maintains Zymeworks $ZYME at Outperform and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Nickhzap
Nickhzap Mar. 9 at 1:09 PM
$ZYME what a surprise! Back to green! womp womp womp 🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡🤡
1 · Reply
Nickhzap
Nickhzap Mar. 9 at 12:25 PM
$ZYME lololol. On 240 shares! 🤡🤡🤡🤡🤡🤡🤡
0 · Reply
BuyingSheep
BuyingSheep Mar. 9 at 8:29 AM
$ZYME
2 · Reply
Nickhzap
Nickhzap Mar. 6 at 10:37 PM
$ZYME Buyingsheep will claim that today was a nasty sell off 🤡🤡🤡🤡
0 · Reply
tdntdn
tdntdn Mar. 6 at 2:52 PM
$ZYME Day One (DAWN) is valued at $2.5 billion after a buyout from Servier. I just feel ZYME is so undervalued based on their pipeline but more importantly their platform to build new molecules. Good luck everyone.
0 · Reply
erevnon
erevnon Mar. 6 at 12:14 PM
HC Wainwright & Co. maintains Zymeworks $ZYME at Buy and raises the price target from $32 to https://marketsblock.com/stock-upgrades-and-downgrades/
1 · Reply
Social_Idiot
Social_Idiot Mar. 5 at 10:20 PM
$ZYME Wow. So many partners.
0 · Reply
DanLefort
DanLefort Mar. 5 at 5:37 PM
$ZYME biotech quietly compressing if catalyst appears volume ignition likely
1 · Reply